Expression of ganglioside GD2 on colorectal adenocarcinoma cells

Lupatov A.Yu.1, Gisina A.M.1, Kim Y.S.1, Bykasov S.A.2, Volchenko N.N.2, Sidorov D.V.2, Yarygin K.N.1, Kholodenko R.V.3

1. Institute of Biomedical Chemistry, Moscow, Russia
2. Hertsen Moscow Oncology Research Center – branch of National Medical Research Radiological Center of the Ministry of Health, Moscow, Russia
3. Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia
Section: Short Communication
DOI: 10.18097/PBMC20206601095      PubMed Id: 32116232
Year: 2020  Volume: 66  Issue: 1  Pages: 95-99
Using flow cytometry GD2 ganglioside expression was evaluated both on colorectal adenocarcinoma cell lines and on tumor tissue samples from colorectal cancer patients. The marker was found on EpCAM-positive tumor cells in 6 of 12 patients' samples but not on the HT29 and CaCo-2 cell lines. GD2 expression was not an exceptional feature of cancer stem cells, since its expression level was similar on CD133-positive and CD133-negative tumor cells. Thus, the presence of GD2 ganglioside was revealed on colorectal adenocarcinoma cells for the first time. This finding makes it possible to use targeted therapy to treat this disease.
Download PDF:  
Keywords: colorectal cancer, GD2 ganglioside, targeted therapy, CD133, EpCAM

Lupatov, A. Yu., Gisina, A. M., Kim, Y. S., Bykasov, S. A., Volchenko, N. N., Sidorov, D. V., Yarygin, K. N., Kholodenko, R. V. (2020). Expression of ganglioside GD2 on colorectal adenocarcinoma cells. Biomeditsinskaya Khimiya, 66(1), 95-99.
This paper is also available as the English translation: 10.1134/S1990750820030099
 2024 (vol 70)
 2023 (vol 69)
 2022 (vol 68)
 2021 (vol 67)
 2020 (vol 66)
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)